Pleryon Therapeutics Limited
Pleryon Therapeutics is dedicated to address unmet medical needs, not only from patients with serious diseases but also general public and pets, by implementing cutting edge drug delivery and biomaterials technologies from bench to bedside. Our current focus is in eye diseases, where the number of effective drugs are abundant but delivery methods aren't. The core technology was developed in the Laboratory of Drug Delivery and Biomaterials from the Hong Kong University of Science and Technology during the past 10 years, by co-founders Dr. Yu Yu and Prof. Ying Chau.
Our first product in the pipeline is at veterinary clinical stage, a hyaluronic acid based artificial tear specially formulated to have a half-life 50 times longer than many existing artificial tears, which we aim to develop as a veterinary and consumer product. We are also dedicated to improving the treatment of posterior neovascularization diseases including age-related macular degeneration (AMD), diabetic retinopathy (DR) and retinal vein occlusion (RVO). These diseases are the major causes of blindness in the developed countries. Our proprietary extra-long-term protein release hydrogel technology has demonstrated to be biocompatible and therapeutically effective for over 5 months in monkey.
Our company is supported by star scientists and entrepreneurs, including Prof. Robert Langer, David H. Koch Institute Professor of MIT, Prof. Glenn Prestwich, Presidential Professor of Medicinal Chemistry at the University of Utah and Prof. Mingguang He, Professor of The University of Melbourne and Professor and Associate Director of Zhongshan Ophthalmic Centre.